Noninvasive Imaging Evaluation Based on Computed Tomography of the Efficacy of Initial Transarterial Chemoembolization to Predict Outcome in Patients with Hepatocellular Carcinoma

References

• McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2021;73(Suppl 1):4–13. doi:10.1002/hep.31288
   PubMed Web of Science ®Google Scholar
• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. doi:10.1038/s41572-020-00240-3
   PubMed Web of Science ®Google Scholar
• Ogasawara S, Ooka Y, Itokawa N, et al. Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan. Invest New Drugs. 2020;38(1):172–180. doi:10.1007/s10637-019-00801-8
   PubMed Web of Science ®Google Scholar
• Ogasawara S, Chiba T, Ooka Y, et al. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. Oncology. 2014;87(6):330–341. doi:10.1159/000365993
   PubMed Web of Science ®Google Scholar
• Raoul JL, Forner A, Bolondi L, et al. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat Rev. 2019;72:28–36. doi:10.1016/j.ctrv.2018.11.002
   PubMed Web of Science ®Google Scholar
• Jimenez Perez M, Grande RG. Application of artificial intelligence in the diagnosis and treatment of hepatocellular carcinoma: a review. World J Gastroenterol. 2020;26(37):5617–5628. doi:10.3748/wjg.v26.i37.5617
   PubMed Web of Science ®Google Scholar
• Kuang Y, Li R, Jia P, et al. MRI-based radiomics: nomograms predicting the short-term response after transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma patients with diameter less than 5 cm. Abdom Radiol (NY). 2021;46(8):3772–3789. doi:10.1007/s00261-021-02992-2
   PubMed Web of Science ®Google Scholar
• Li L, Kan X, Zhao Y, et al. Radiomics signature: a potential biomarker for the prediction of survival in advanced hepatocellular carcinoma. Int J Med Sci. 2021;18(11):2276–2284. doi:10.7150/ijms.55510
   PubMed Web of Science ®Google Scholar
• Meng XP, Wang YC, Ju S, et al. Radiomics analysis on multiphase contrast-enhanced CT: a survival prediction tool in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Front Oncol. 2020;10:1196. doi:10.3389/fonc.2020.01196
   PubMed Web of Science ®Google Scholar
• Han G, Berhane S, Toyoda H, et al. Prediction of survival among patients receiving transarterial chemoembolization for hepatocellular carcinoma: a response-based approach. Hepatology. 2020;72(1):198–212. doi:10.1002/hep.31022
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. doi:10.1002/hep.29086
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60. doi:10.1055/s-0030-1247132
   PubMed Web of Science ®Google Scholar
• Llovet JM, Lencioni R. mRECIST for HCC: performance and novel refinements. J Hepatol. 2020;72(2):288–306. doi:10.1016/j.jhep.2019.09.026
   PubMed Web of Science ®Google Scholar
• Buvat I, Orlhac F, Soussan M. Tumor texture analysis in PET: where do we stand? J Nucl Med. 2015;56(11):1642–1644. doi:10.2967/jnumed.115.163469
   PubMed Web of Science ®Google Scholar
• Kawamura Y, Ikeda K, Hirakawa M, et al. New classification of dynamic computed tomography images predictive of malignant characteristics of hepatocellular carcinoma. Hepatol Res. 2010;40(10):1006–1014. doi:10.1111/j.1872-034X.2010.00703.x
   PubMed Web of Science ®Google Scholar
• Kaul V, Enslin S, Gross SA. History of artificial intelligence in medicine. Gastrointest Endosc. 2020;92(4):807–812. doi:10.1016/j.gie.2020.06.040
   PubMed Web of Science ®Google Scholar
• Choi GH, Yun J, Choi J, et al. Development of machine learning-based clinical decision support system for hepatocellular carcinoma. Sci Rep. 2020;10(1):14855. doi:10.1038/s41598-020-71796-z
   PubMed Web of Science ®Google Scholar
• Zhang Z, Chen J, Jiang H, et al. Gadoxetic acid-enhanced MRI radiomics signature: prediction of clinical outcome in hepatocellular carcinoma after surgical resection. Ann Transl Med. 2020;8(14):870. doi:10.21037/atm-20-3041
   PubMed Web of Science ®Google Scholar
• Wu K, Shui Y, Sun W, et al. Utility of radiomics for predicting patient survival in hepatocellular carcinoma with portal vein tumor thrombosis treated with stereotactic body radiotherapy. Front Oncol. 2020;10:569435. doi:10.3389/fonc.2020.569435
   PubMed Web of Science ®Google Scholar
• Kim J, Choi SJ, Lee SH, et al. Predicting survival using pretreatment CT for patients with hepatocellular carcinoma treated with transarterial chemoembolization: comparison of models using radiomics. AJR Am J Roentgenol. 2018;211(5):1026–1034. doi:10.2214/AJR.18.19507
   PubMed Web of Science ®Google Scholar
• Niu XK, He XF. Development of a computed tomography-based radiomics nomogram for prediction of transarterial chemoembolization refractoriness in hepatocellular carcinoma. World J Gastroenterol. 2021;27(2):189–207. doi:10.3748/wjg.v27.i2.189
   PubMed Web of Science ®Google Scholar
• Chun SH, Suh YJ, Han K, et al. Differentiation of left atrial appendage thrombus from circulatory stasis using cardiac CT radiomics in patients with valvular heart disease. Eur Radiol. 2021;31(2):1130–1139. doi:10.1007/s00330-020-07173-1
   PubMed Web of Science ®Google Scholar
• Zhou J, Lu J, Gao C, et al. Predicting the response to neoadjuvant chemotherapy for breast cancer: wavelet transforming radiomics in MRI. BMC Cancer. 2020;20(1):100. doi:10.1186/s12885-020-6523-2
   PubMed Web of Science ®Google Scholar
• Mahmood U, Apte AP, Deasy JO, et al. Investigating the robustness neighborhood gray tone difference matrix and gray level co-occurrence matrix radiomic features on clinical computed tomography systems using anthropomorphic phantoms: evidence from a multivendor study. J Comput Assist Tomogr. 2017;41(6):995–1001. doi:10.1097/RCT.0000000000000632
   PubMed Web of Science ®Google Scholar
• Duan J, Hu C, Qiu Q, et al. Characterization of microvessels and parenchyma in in-line phase contrast imaging CT: healthy liver, cirrhosis and hepatocellular carcinoma. Quant Imaging Med Surg. 2019;9(6):1037–1046. doi:10.21037/qims.2019.06.12
   PubMed Web of Science ®Google Scholar
• Harding-Theobald E, Louissaint J, Maraj B, et al. Systematic review: radiomics for the diagnosis and prognosis of hepatocellular carcinoma. Aliment Pharmacol Ther. 2021;54(7):890–901. doi:10.1111/apt.16563
   PubMed Web of Science ®Google Scholar
• Park HJ, Kim JH, Choi SY, et al. Prediction of therapeutic response of hepatocellular carcinoma to transcatheter arterial chemoembolization based on pretherapeutic dynamic CT and textural findings. AJR Am J Roentgenol. 2017;209(4):W211–W220. doi:10.2214/AJR.16.17398
   PubMed Web of Science ®Google Scholar
• Kim CJ, Kim HJ, Park JH, et al. Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma. Liver Int. 2014;34(2):305–312. doi:10.1111/liv.12270
   PubMed Web of Science ®Google Scholar
• Lee JS, Choi HJ, Kim BK, et al. The Modified Response Evaluation Criteria in Solid Tumors (RECIST) yield a more accurate prognoses than the RECIST 1.1 in hepatocellular carcinoma treated with transarterial radioembolization. Gut Liver. 2020;14(6):765–774. doi:10.5009/gnl19197
   PubMed Web of Science ®Google Scholar
• Hasdemir DB, Davila LA, Schweitzer N, et al. Evaluation of CT vascularization patterns for survival prognosis in patients with hepatocellular carcinoma treated by conventional TACE. Diagn Interv Radiol. 2017;23(3):217–222. doi:10.5152/dir.2016.16006
   PubMed Web of Science ®Google Scholar
• Kim Y, Stahl CC, Makramalla A, et al. Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria. Surgery. 2017;162(6):1250–1258. doi:10.1016/j.surg.2017.08.007
   PubMed Web of Science ®Google Scholar
• Orlacchio A, Chegai F, Merolla S, et al. Downstaging disease in patients with hepatocellular carcinoma outside up-to-seven criteria: strategies using degradable starch microspheres transcatheter arterial chemo-embolization. World J Hepatol. 2015;7(12):1694–1700. doi:10.4254/wjh.v7.i12.1694
   PubMedGoogle Scholar
• Montasser A, Beaufrère A, Cauchy F, et al. Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma. Histopathology. 2021;79(1):36–46. doi:10.1111/his.14317
   PubMed Web of Science ®Google Scholar
• Toso C, Mentha G, Kneteman NM, et al. The place of downstaging for hepatocellular carcinoma. J Hepatol. 2010;52(6):930–936. doi:10.1016/j.jhep.2009.12.032
   PubMed Web of Science ®Google Scholar
• Peng ZW, Zhang YJ, Chen MS, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol. 2013;31(4):426–432. doi:10.1200/JCO.2012.42.9936
   PubMed Web of Science ®Google Scholar
• Song JE, Kim DY. Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma. World J Hepatol. 2017;9(18):808–814. doi:10.4254/wjh.v9.i18.808
   PubMed Web of Science ®Google Scholar
• Tu R, Zhang YD, Wu BZ, et al. Study of CT grading of liver cirrhosis. Radiol Pract. 2003;18(9):621–623.
   Google Scholar